Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lung disease

- PMLiVE

AZ gets injunction to protect Pulmicort Respules

Actavis blocked from selling generic five days after AZ’s asthma launch

- PMLiVE

AstraZeneca employs Wolfram tech for liver health research

Project could produce mathematical models that can detect liver problems

- PMLiVE

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins

- PMLiVE

AZ adds to respiratory portfolio with Actavis drugs

Follows deal to acquire Almirall’s franchise in asthma and COPD

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

- PMLiVE

AZ signs yet another cancer immunotherapy deal

Will work with Omnis to develop viruses that target tumour cells

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links